Novo Nordisk announced it is discontinuing its cell therapy R&D efforts as part of a company-wide reorganization under new leadership, laying off nearly all employees in the shuttered unit and ending work on programs that included a cell-therapy approach for Type 1 diabetes. Media outlets and company statements outlined the cuts and strategic refocus. Lead sentence: Novo halted its cell therapy division, terminating roughly 250 roles and signaling a strategic pivot that will reallocate resources toward priority therapeutic areas such as obesity and diabetes drugs rather than cell modalities. The company characterized the move as part of a cost-savings plan to improve focus and efficiency. Industry observers noted the decision follows a broader retreat by several large pharmas from cell-therapy research this year and may accelerate partner-seeking for orphaned programs or redirect investments toward in vivo approaches and small molecules. The company’s public comment was the primary source for the move.